One of the defining features of heart failure (HF) is neurohormonal activation. The renin-
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …

Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …

The new Universal Definitionfor Heart Failure partitions heart failure phenotypes according
to ejection fraction criteria. 1 For those with signs and symptoms of heart failure and a …

Purpose of review Compared to enalapril, use of angiotensin-receptor blocker and
neprilysin inhibitor sacubitril/valsartan to treat patients with heart failure and reduced …

Aims The poor control of symptoms in patients with advanced heart failure with reduced
ejection function (HFrEF) can limit the functionality of patients. Sacubitril–valsartan …

Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …

Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that has
been recommended in clinical practice guidelines to reduce morbidity and mortality in …

With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has
become a milestone in the treatment of patients with chronic heart failure (HF) with reduced …

Abstract Aims The PARADIGM‐HF trial showed that sacubitril–valsartan, an ARB–neprilysin
inhibitor, is more effective than enalapril for some patients with heart failure (HF). It is …